ASCO 2025: Building a stronger future in cancer care with a ...

From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the

IMUNON at ASCO 2025: Changing the micro-tumour environment i...

Treating primary bone cancer: The potential of listeria-base...

In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.

Beyond traditional cancer treatment: Can we confront unmet n...

Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bl...

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.